Mentalization-based treatment for female patients with comorbid personality disorder and substance use disorder: A pilot study

Our pilot study indicates that mentalization-based treatment may be a promising treatment modality for female patients with comorbid substance use disorder and borderline personality disorder, write Katharina T. E. Morken and colleagues.

BY: Katharina T. E. Morken, Per-Einar Binder, Helge Molde, Nina Arefjord and Sigmund Karterud

One possible way of understanding substance use is by seeing it as one of several self-soothing strategies utilized by patients who struggle with personality problems (e.g., emotional dysregulation and social deficiencies) (Philips, Kahn, & Bateman, 2012).

Substance use disorder (SUD) and personality disorder (PD) are frequently co-occurring but clinically their comorbidity is often ignored or treated separately; in some institutions, SUD is even considered an exclusion criterion in treatment programs for PD.

There is no doubt that the comorbidity between personality disorder and substance use disorder overall is high. Numerous studies have demonstrated the frequent covariance between these two disorders (Cacciola, Alterman, Rutherford, McKay, & Mulvaney, 2001; Fenton et al., 2012; Hasin & Kilcoyne, 2012; McGlashan et al., 2000; Thomas, Melchert, & Banken, 1999; Trull, Jahng, Tomko, Wood, & Sher, 2010; Verheul, 2001). It has been debated whether it is PD in general or Cluster B specifically that drives the covariation. It has also been discussed if the covariance can be explained by overlapping criteria (e.g., impulsivity in borderline personality disorder (BPD) and antisocial PD).

For example, in one study of opiate use disorders in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 50% of respondents had a PD. When controlling for the general criteria for PD, borderline personality disorder became a clear predictor for SUD (Jahng et al., 2011). It has been suggested that the covariation between BPD and SUD are linked via impulsivity (Jahng et al., 2011; McGlashan et al., 2000). Among SUD patients, a median of 57% (range 35%–73%) had concurrent PD (Verheul, 2001), and among PD in the general population, the prevalence of comorbid SUD was 42% for alcohol and 19% for substance use (Trull et al., 2010).
In Scandinavian samples, the co-occurrence of SUD in PD in a population-based study was 46% (Toftdahl, Nordentoft, & Hjorthøj, 2016). For female patients with SUD, BPD is the most common personality disorder (Landheim, Bakken, & Vaglum, 2003). Cluster B personality traits have been found to be independent risk factors for developing SUD (Cohen, Chen, Crawford, Brook, & Gordon, 2007; Walter et al., 2009). BPD has been found as a significant risk factor for the persistence of SUD (Fenton et al., 2012), but remission of SUD in BPD in a 10-year study was also common (Zanarini et al., 2011). Treatment of patients with BPD/SUD has been described as difficult due to high dropout rates and to relational problems that make the process of establishing a therapeutic alliance challenging (Karterud, Arefjord, Andresen, & Pedersen, 2009).

For instance, Cluster B traits present a barrier in forming a therapeutic alliance with SUD patients and Cluster B traits have been found to provoke distanced and overwhelmed/disorganized countertransference in helpers (Betan, Heim, Conklin, & Westen, 2005; Olesk et al., 2016; Thylstrup & Hesse, 2008). Concurrent PD/SUD results in a more serious substance use disorder and more substance use–related problems (Vélez-Moreno et al., 2016). Risk for suicide attempts is higher for BPD patients with comorbid SUD compared to BPD or SUD patients alone (Darke, Williamson, Ross, Teesson, & Lynskey, 2004; Yen et al., 2003), although one study found no correlation between suicide attempts and baseline PD (Bakken & Vaglum, 2007). Risk for treatment attrition is higher for PD/SUD compared to SUD alone (Ball, Carroll, Canning-Ball, & Rounsaville, 2006; Brorson, Arnevik, Rand-Hendriksen, & Duckert, 2013; Cacciola et al., 2001). In addition, Cluster B traits and a PD diagnosis have been found to influence outcome negatively for SUD patients (Marlowe, Kirby, Festinger, Husband, & Platt, 1997; Thomas et al., 1999), although in one study PD had no influence on the outcome of SUD at a six-year follow-up (Landheim, Bakken, & Vaglum, 2006).

Thus, when BPD and SUD co-occur, the patients seem to be struggling even more than when each of these serious disorders occurs alone, and therapeutically there are many pitfalls. Patients with dual diagnoses are marginalized, often excluded from psychiatric treatments, and most likely need additional support (Toftdahl, Nordentoft, & Hjorthøj, 2016). Many have voiced the need for targeted treatments for this group of patients (Hesse & Fridell, 2009; Ravndal, Vaglum, & Lauritzen, 2005; Vélez-Moreno et al., 2016).
Concerning evidence for efficacy of psychotherapy for BPD/SUD, the latest review found 10 controlled studies on BPD/SUD patients (Lee, Cameron, & Jenner, 2015). The studies included four studies with dialectical behavioral therapy (DBT), three with dual focused schema therapy (DFST), and three with dynamic deconstructive psychotherapy (DDP). DBT and DDP showed some reduction in symptoms and substance use while DFST had minimal effect on outcome. The authors conclude that the evidence base for treatment of co-occurring BPD/SUD needs more research and that some preliminary evidence exists to date in benefit of DBT and DDP.

Mentalization-based treatment has shown great promise with BPD patients in various RCTs and naturalistic cohort studies, both within the original environment (Bateman & Fonagy, 2001, 2009; Rossouw & Fonagy, 2012) and from other independent institutions (Bales et al., 2014; Bales et al., 2012; Jørgensen et al., 2014; Kvarstein et al., 2015). In some studies (Bateman & Fonagy, 2009; Jørgensen et al., 2013), the difference between the control condition (structured clinical management, supportive group psychotherapy) and MBT has not been that large regarding outcome. However, the superiority of MBT has been demonstrated when the severity of PD is taken into consideration (Bateman & Fonagy, 2013).

To date, there is only one unpublished study from Stockholm on MBT for BPD/SUD. In this RCT, patients received 18 months of MBT or treatment as usual (TAU) within an outpatient addiction treatment clinic. Surprisingly, the MBT patients (N=24) did not differ from the control group (N = 22) with respect to outcome. There was one near significant finding (Mann-Whitney p = 0.06) that demonstrated the MBT group had no suicide attempts during treatment, versus four in the control group (Philips, 2016). However, we cannot know for sure that treatment in this study was MBT proper since adherence was low (Karterud & Bateman, 2010; Möller, Karlsgren, Sandell, Falkenström, & Philips, 2016; Philips, 2016). Another study on MBT with severely impaired young BPD patients involved 79% with comorbid SUD. In this study, MBT showed improvement on several outcome measures, and effect sizes were large (Bales et al., 2012).

Thus, to date, we still do not know whether MBT is an efficient approach for BPD/SUD patients. It could be that the presence of SUD has some consequences for treatment that we still do not fully understand. We have tentative knowledge that BPD/SUD patients seem to improve after MBT, but we also have knowledge of the opposite: no improvement at all. Many have advocated the importance of tailoring treatments to these patients who are so severely disordered. Still, we have only preliminary evidence that
specialized treatment (e.g., DBT) for this patient group is beneficial (Lee et al., 2015). Against this backdrop, we aimed to investigate in a pilot project if MBT, a specialized tailored treatment for BPD, is promising in the treatment of a group of severely disordered dual diagnosis patients with BPD/SUD. Furthermore, we strove to investigate the feasibility aspects of implementation, delivery by clinicians, and acceptability for patients in order to clarify whether a larger study could be recommended on this population and within this context.

**Research questions**

Does mentalization-based treatment have any positive effect on BPD/SUD patients’ substance use and personality disorder (primary outcome)? Does mentalization-based treatment have any positive effect on symptom distress and/or interpersonal and social functioning (secondary outcome)? Is MBT feasible as a treatment and for investigation in a larger study format in a general drug clinic on female patients with dual PD/SUD?

**Material and Methods**

**Subjects**

Patients were recruited from the inpatient and outpatient facilities of the Bergen Clinic Foundation (BCF). Patients in the BCF consist of both inpatients and outpatients with SUD, the majority with alcohol use disorder (40%–45%) and then equally distributed SUD diagnosis among cannabis, benzodiazepines and amphetamine dependency as most frequent. Multiple substance use is common; most patients have more than one SUD diagnosis. Most patients are without occupation (78%) and supported by different economic welfare benefits (75%–80%). A minority of the patients are female (27%) (Skutle, 2017). Because the BCF has an explicit focus on gender-specific treatment where males and females are given separate treatments, this pilot was performed with female patients alone. We went out broadly in the clinic asking for participants who were “difficult to treat,” female, and with a tentative diagnosis of BPD. Eighteen patients were included in the project. Inclusion criteria included being female and having a diagnosis of SUD together with a personality disorder with clinically significant borderline traits according to the SCID-II (Gibbon, Spitzer, & First, 1997). The full diagnosis of BPD was not necessary to enter the pilot. Exclusion criteria were diagnosis of schizophrenia and substitute opiate medication. See Table 2 for diagnostic profiles.

The patients were severely impaired, and all had histories of trauma. Seven of 18 had histories with rape, eight had been victims of violence in childhood, 10 had a history of neglect in childhood, and seven had experienced sexual trauma in childhood. Most patients
had problems with violence and aggression. Ten of 18 had been
violent toward people, 14 of 18 had been violent to material objects,
and seven of 18 had been reported to the police for violent offences.
Six patients had a prior history of psychotic episodes but not a
diagnosis of schizophrenia. Their history of prior treatment was quite
substantial, with a mean of four (range 1–15) prior admissions to
inpatient treatment and a mean of three (range 1–7) periods of
outpatient treatment.

They had a mean of two (range 1–4) SUD diagnoses and a mean of
four (range 1–7) Axis I diagnoses at baseline. (See Table 2 for
diagnostic characteristics.) All patients had maladaptive traits within
the BPD category (range 3–9 traits). As for PD traits according to
SCID-II, they had a mean of 18 (range 9–42) PD traits. The
distribution of PDs can be seen in Table 3. Nine patients had more
than one PD (range 2–5 PDs).

Clinical vignettes on one patient are hereby included to demonstrate
a typical patient in this project:

**Patient 1**

*Female patient, 28 years old, antisocial PD/BPD, polysubstance use
disorder, and ADHD. History of neglect and conduct disorder in
childhood. Before treatment, she uses amphetamine daily
intravenously and in addition opiates and benzodiazepines. During
assessment, she gets an ADHD diagnosis and starts on appropriate
medication. Her level of functioning is very low, with a GAF score of
37. She has frequent impulsive, aggressive outbursts with people
around her, both strangers and close relations. She gets easily
agitated and sometimes uses violence or threats of violence. She is
unemployed and receives welfare benefits. She finished two years of
MBT. At follow-up she describes being abistent from all drugs for
the last four years. She has much fewer conflicts with others
because she is able to see situations from the other’s perspective.
She has started a part-time job and deals with the relational aspect
of working by thinking things through instead of acting out on
colleagues. She is very grateful for the treatment that helped her.*

Patients were assessed prior to treatment, every six months during
treatment, and at follow-up. The number of measurement points per
patient varied with a mean of four (range 2–6). All patients were
invited via post to participate in a follow-up assessment. They
received a gift certificate of 500 NOK (60 Euro / 60 U.S. dollars) for
participation. Thirteen patients participated. Five patients did not
participate in the follow-up. Some descriptive data and length of
treatment are included below. Their reasons for not participating in
the follow-up were: 1) One patient threatened suicide if we ever
contacted her again (13 months MBT); 2) one patient was of
unknown whereabouts in another continent, and her family had no idea where and when she would be back (10 months MBT); 3) one patient angrily said no and hung up the telephone (six months MBT); 4) one patient agreed to come to follow-up but never showed up, and she never answered our requests again (one month MBT); 5) one patient was severely ill after a drug-related incident and was chronically hospitalized and unable to perform assessment (seven months MBT). Thus, compared to follow-up attendees, the mean duration of treatment was lower (seven vs. 22 months).

Follow-up assessments were performed at a mean of 22 (SD = 18) months after termination of MBT. In the follow-up, the pre-treatment battery was repeated together with qualitative interviews.

<table>
<thead>
<tr>
<th>18 patients agreed to participate in the pilot</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 completed MBT (≥ 7 months)</td>
</tr>
<tr>
<td>4 dropouts (≤ 6 months)</td>
</tr>
<tr>
<td>11 participated in follow-up assessment</td>
</tr>
<tr>
<td>2 participated in follow-up assessment</td>
</tr>
</tbody>
</table>

**FIGURE 1:** Patient flow in 36 months of MBT and follow-up at 22 months post-treatment.

**TABLE 1:** Demographic characteristics of patients at baseline (N = 18).
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Mean / SD</th>
<th>N / %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>30 (8)</td>
<td></td>
</tr>
<tr>
<td>Less than or up to 6 months of work/study last year</td>
<td>14 (78%)</td>
<td></td>
</tr>
<tr>
<td>Years of education after junior secondary school</td>
<td>3 (2)</td>
<td></td>
</tr>
<tr>
<td>Living with partner/children/other</td>
<td>6 (33%)</td>
<td></td>
</tr>
<tr>
<td>Living alone/with parents</td>
<td>12 (67%)</td>
<td></td>
</tr>
<tr>
<td>On disability/social welfare</td>
<td>13 (72%)</td>
<td></td>
</tr>
<tr>
<td>Civil status:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>14 (78%)</td>
<td></td>
</tr>
<tr>
<td>Cohabitated</td>
<td>2 (11%)</td>
<td></td>
</tr>
<tr>
<td>Divorced/ separated</td>
<td>2 (11%)</td>
<td></td>
</tr>
<tr>
<td>Living with:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parents</td>
<td>5 (28%)</td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td>4 (22%)</td>
<td></td>
</tr>
<tr>
<td>Alone</td>
<td>7 (39%)</td>
<td></td>
</tr>
<tr>
<td>Partner/Other</td>
<td>2 (11%)</td>
<td></td>
</tr>
<tr>
<td>Mean submissions to inpatient psychiatric hospitals</td>
<td>4 (4)</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 2**: Clinical characteristics of patients at baseline (*N* = 18).
<table>
<thead>
<tr>
<th>Axis I disorders</th>
<th>Mean / SD</th>
<th>N / %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harmful use/dependency alcohol</td>
<td></td>
<td>12 (67%)</td>
</tr>
<tr>
<td>Harmful use/dependency benzodiazepines</td>
<td></td>
<td>5 (28%)</td>
</tr>
<tr>
<td>Harmful use/dependency opioids</td>
<td></td>
<td>5 (28%)</td>
</tr>
<tr>
<td>Harmful use/dependency cannabinoids</td>
<td></td>
<td>5 (28%)</td>
</tr>
<tr>
<td>Harmful use/dependency amphetamine</td>
<td></td>
<td>5 (28%)</td>
</tr>
<tr>
<td>Mood/anxiety disorders</td>
<td></td>
<td>14 (78%)</td>
</tr>
<tr>
<td>Any eating disorder</td>
<td></td>
<td>3 (17%)</td>
</tr>
<tr>
<td>Attention deficit hyperactivity disorder</td>
<td></td>
<td>1 (6%)</td>
</tr>
<tr>
<td>Post-traumatic stress disorder</td>
<td></td>
<td>3 (17%)</td>
</tr>
<tr>
<td>Obsessive-compulsive disorder</td>
<td></td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Mean number PD diagnosis</td>
<td></td>
<td>2 (1)</td>
</tr>
<tr>
<td>SCID-II PD criteria</td>
<td></td>
<td>18 (9)</td>
</tr>
<tr>
<td>Borderline personality disorder criteria</td>
<td></td>
<td>5 (2)</td>
</tr>
<tr>
<td>Axis I disorders, mean number</td>
<td></td>
<td>4 (2)</td>
</tr>
<tr>
<td>Axis I substance use disorders, mean number</td>
<td></td>
<td>2 (1)</td>
</tr>
</tbody>
</table>

**TABLE 3:** Personality disorders at baseline (N = 18).

<table>
<thead>
<tr>
<th>Personality disorders at baseline</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borderline personality disorder</td>
<td>11 (61%)</td>
</tr>
<tr>
<td>Antisocial personality disorder</td>
<td>3 (17%)</td>
</tr>
<tr>
<td>Avoidant personality disorder</td>
<td>5 (28%)</td>
</tr>
<tr>
<td>Dependent personality disorder</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>Schizotypal personality disorder</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Paranoid personality disorder</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Obsessive compulsive personality disorder</td>
<td>3 (17%)</td>
</tr>
<tr>
<td>Histrionic personality disorder</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Narcissistic personality disorder</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>Schizoid personality disorder</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>PD NOS</td>
<td>3 (17%)</td>
</tr>
</tbody>
</table>

8/30
Dual focus mentalization-based treatment

Training in MBT consisted of a three-day introductory course and a one-year specialization course (eight days). In addition, therapists received weekly video supervision with an expert in MBT and monthly video supervision with an external supervisor, also expert in MBT. Treatment was performed according to group and individual manuals (Karterud, 2011, 2012; Karterud & Bateman, 2010). Adherence was not measured, but weekly video supervision was conducted according to the manuals. Patients started out with 12 sessions of MBT psychoeducation and then continued with the group (MBT-G) and individual therapy (MBT-I). Maximal treatment duration was three years and involved weekly individual and group sessions throughout the entire period. Mean months in treatment were 22 (SD = 15). In dual focus MBT, focus on the mental function of SUD is of importance. Incidents of substance use are considered important and the focus is on exploring the mentalizing failure and interpersonal context prior to intake. All patients had access to a social counselor who was trained in MBT and who attended the supervisory sessions. The task of the social counselor was to offer help with social functioning in addition to increasing mentalization both there and then subsequently in encounters with the social welfare system, child protective services, and the like. The social counselor also did a thorough mapping of the patients’ social, economic, and work status and offered help with attaining their goals in social and work functioning.

Diagnostics

All therapists were trained in GAF and SCID-II assessments from a supervisor from the Norwegian Network of Personality-Focused Treatment Programs, and the assessment procedures were equal to those used by this network. (See for instance Kvarstein et al., 2015). Diagnostic reliability was not measured, but therapists were specially trained in the diagnostics of PD, and diagnoses were discussed thoroughly within the team and with the supervisor. In addition, according to the LEAD principle, diagnoses were open for adjustments during the clinical trajectory (Spitzer, 1983). At follow-up, diagnostics were performed by the first and fourth authors, who together evaluated SCID, GAF, and MINI diagnosis of all patients. Both also performed the diagnostic interviews.

Outcome measures

Axis I SUD diagnosis

Patients were interviewed with the Mini-International Neuropsychiatric Interview-Plus (M.I.N.I-Plus) before treatment and
at follow-up (Sheehan et al., 1998). M.I.N.I-Plus is a structured
diagnostic interview covering the most prevalent Axis I disorders
within both DSM-IV and ICD-10.

Axis II disorders
Patients were diagnosed on Axis II by clinical interviews before
treatment and at follow-up according to the Structured Clinical
Interview for DSM-IV (SCID-II) (Gibbon et al., 1997). Following the
LEAD principle, some of the diagnoses were revised after further
clinical observation during the treatment period (Spitzer, 1983). The
SCID-II is a semi-structured 94-item clinical interview that
investigates the presence of PD according to the criteria from DSM-
IV. Questions are answered with a yes or no and then further
investigated through probing for examples. The interviewer decides
if a patient fulfills criteria on SCID-II based on all available clinical
information in addition to answers given during the interview.

SCL-90-R symptom distress
Symptoms were measured with SCL-90-R (Derogatis, 1977). The
General Severity Index (GSI) is a well-known symptom distress
measure and is widely used within clinical psychotherapy research.
GSI gives a broad picture of a patient’s symptom distress in general.
It is an average score of the total 90 items. The clinical/non-clinical
cutoff level is set at GSI = 0.8 for women based on a Norwegian
patient sample (Pedersen & Karterud, 2004). Cronbach’s alpha at
baseline = 0.89.

Interpersonal functioning
Interpersonal functioning was measured as the Circumplex of
Interpersonal Problems (CIP) (Pedersen, 2002), which is a
Norwegian short version of the IIP-C (Horowitz, Rosenberg, Baer,
Ureño, & Villaseñor, 1988). The mean sum score (CIP) correlates
highly ($r = 0.99$) with the original IIP-C sum score (Pedersen, 2002).
The clinical cutoff score of CIP is 0.8 (i.e., one standard deviation
above mean IIP sum scores ($M = 0.53$) in a non-clinical Norwegian
population) (Kvarstein et al., 2015; Pedersen, 2002). CIP has 48
items with a five-point scale, where subjects rate the degree of
interpersonal problems. The CIP sum score is an indicator of the
general level of experienced interpersonal problems and is based on
a mean average of all 48 items. Cronbach’s alpha at baseline $= 0.56$.

Global assessment of functioning
The Global Assessment of Functioning (GAF) scale (Hall, 1995) is a
widely used rating scale, ranging from 0 to 100, where 100
represents maximal global functioning (Pedersen & Karterud, 2012).
GAF has shown high reliability between experienced judges and is a
quick and easy instrument that can be used for measuring an
individual patient’s need for treatment and at which level of health care (Pedersen, Haqtvet, & Karterud, 2007). A score of 60 indicates mild symptoms or impairment and is considered a good cutoff indicator for functional impairment in studies with treatment of PD (Kvarstein & Karterud, 2012).

**Self-esteem**
The Rosenberg Self-Esteem Scale (RSES) is a 10-item self-report questionnaire (Rosenberg, 1986). The 10 items are rated on a four-point scale from “strongly disagree” (1) to “strongly agree” (4). Cutoff for “normal” self-esteem lies at 3 (+/- 0.4). According to one study across 53 nations, RSES has good internal consistency with a mean Cronbach’s alpha coefficient reported of 0.81 (Schmitt & Allik, 2005). In the current study, Cronbach’s alpha at baseline was 0.89.

**Work and social functioning scale**
The Work and Social Adjustment Scale (WSAS) is a five-item self-report questionnaire (Mundt, Marks, Shear, & Greist, 2002). The five items are rated on an eight-point scale from “not impaired at all” to “severely impaired,” the responses to which are based on the last four weeks of functioning. The scoring range goes from 0 to 40, where a score above 20 represents severe psychopathology and functional impairment while a score between 10 and 20 represents functional impairment but less severe clinical symptomology. The cutoff score between clinical and non-clinical populations lies at 10. Cronbach’s alpha at baseline = 0.85.

**Treatment retention**
In this study, we defined dropout as less than or equal to six months of treatment, following the definition by Kvarstein and colleagues (2015) and the definition of “early dropouts” by Bateman & Fonagy (2009). In a study where the treatment duration is up to 36 months, we considered greater than six months to be a reasonable measure of dropout. Different MBT studies have varied in how they operationalize dropout from greater than three months (Laurensen et al., 2013) to greater than two years (Jørgensen et al., 2013).

**Statistical procedures**
Linear mixed models (LMMs) were used for statistical analysis of the longitudinal data (Singer & Willett, 2003). For psychotherapy research, traditional data analytic techniques like Anova contain restrictive assumptions of sphericity (equal error variance across time points). They also utilize group means and variances and thus have several problems with handling missing data. Missing data have to be expected to some degree in naturalistic clinical settings, and if therapy is assumed to be efficient, larger variability at the start of the treatment is expected compared to the follow-up assessment (Tasca & Gallop, 2009). Thus, LMMs are tailored for psychotherapy
research data in naturalistic settings, because doing so does not require data to meet the sphericity assumption. At the same time, it allows individuals to have different waves of data. The primary outcome data were measured at start of treatment and at follow-up (two timepoints); those were number of SCID-II PD traits, number of SCID-II borderline traits, and number of SUD diagnoses. The longitudinal secondary outcome data with 12 timepoints consisted of CIP, GAF, WSAS, GSI, and RSES. We performed a visual inspection of the data to determine whether a linear or nonlinear model best fitted the data and found that a linear model was a good fit. Time was modeled as a continuous variable with 6-month intervals and with baseline as time zero. Due to a low number of N, we allowed only random effects at baseline and kept the change over time as a fixed effect. Random effects at baseline imply that we allow the intercept to vary across individuals, and by keeping the slope as a fixed effect, we estimate the mean change over time across individuals. Due to a large amount of missing data across patients and measurement occasions, we imputed 20 data sets using the R package “mitml,” or “Tools for Multiple Imputation in Multilevel Modeling” (Grund, Robitzsch, & Lüdtke, 2017). We used the default inverse-Wishart priors, which give the minimum degrees of freedom with the largest dispersion. Furthermore, we used 50,000 burn-ins, 10,000 iterations apart. Estimates and standard errors were aggregated across the multiple imputed data sets (Barnard & Rubin, 1999), adjusting for smaller sample sizes using 28 degrees of freedom.

We calculated effect sizes’ pseudo R² using the bivariate correlation between predicted scores and observed scores. We then transformed R² to Cohen’s d through the formula $d = 2r/\sqrt{(1 - r^2)}$ for pedagogical interpretative purposes. Analyses were performed with IBM 2015 SPSS statistics 23 and the R version 3.4.2 (2017, The R Foundation for Statistical Computing).

**Patient consent**

All patients received written information that explained the purpose of the study and allowed them to withdraw at any time. All the participants gave their written consent. The study was approved by the Regional Ethical Committee West (REK vest) for medical research in Norway.

**Results**

**Primary outcome: Substance use and personality disorder**

*Axis I SUD diagnosis*

At baseline, patients ($N = 18$) had a predicted mean of 1.78 ($SE = 0.20$) SUD diagnoses, and at follow-up, they had a predicted mean of 0.16 ($SE = 0.19$) SUD diagnoses. The change from pre-treatment
to follow-up on SUD diagnosis was highly significant at the two-tailed level ($t(28) = -6.26, p < .001$). The effect size was very large ($d = 2.12$).

**SCID-II personality traits**
Prior to MBT, patients had a predicted mean of 17.72 ($SE = 1.97$) PD traits. At follow-up PD traits had declined to a predicted mean of 7.89 ($SE = 1.83$). The difference was highly significant at the two-tailed level ($t(28) = -3.71, p = .001$). The effect size was large ($d = 1.31$).

**Borderline traits**
At start of treatment, patients ($N = 18$) had a predicted mean of 5.39 ($SE = 0.45$) borderline traits according to the SCID-II interview. At follow-up the patients’ predicted mean of borderline traits had declined to 2.00 ($SE = 0.43$). The change from baseline to follow-up was highly significant at the two-tailed level ($t(28) = -6.24, p < .001$). The effect size was very large ($d = 1.94$). Only two out of 13 patients still fulfilled the criteria for BPD (five and six traits) at follow-up.

**Secondary outcome measures**

**Symptom distress**
At baseline, patients had a predicted mean GSI of 1.25 ($SE = 0.14$). Their GSI declined to a predicted mean of 0.57 ($SE = 0.07$) at follow-up. Change over time for GSI was significant ($t(28) = -2.93, p = .028$). The effect size was large ($d = 1.18$). The predicted mean change per six months was -0.06 ($SE = 0.02$). Nine out of 13 patients were below the clinical cutoff at follow-up assessment (GSI ≤ 0.8).

**Interpersonal functioning**
At baseline, the predicted mean of CIP was 1.28 ($SE = 0.10$). It decreased to a predicted mean of 0.90 ($SE = 0.07$) at follow-up. Effect size for change over time in CIP was moderate ($d = 0.71$) and change from baseline to follow-up was near significant ($t(28) = -2.26, p = .073$). The predicted mean change per six months was -0.03 ($SE = 0.02$). Concerning the clinical cutoff (0.8), six out of 13 patients were below or equal to that at follow-up assessment (CIP ≤ 0.8).

**Global assessment of functioning**
At baseline, patients had a predicted mean of GAF at 46.89 ($SE = 2.15$). At follow-up, their predicted GAF score had increased to 67.81 ($SE = 1.00$). Change over time for GAF was significant ($t(28) = 4.64, p = .004$) and the change rate per six months was 1.90 ($SE = 0.41$). The effect size was large ($d = 2.06$). Looking at the clinical cutoff with a GAF score above the level of 60, 10 out of 13 patients were assessed to be higher or equal to 60 at follow-up.
**Self-esteem**  
RSES at start of treatment had a predicted mean of 2.34 (SE = 0.15). This figure increased to a predicted mean of 3.06 (SE = 0.10) at follow-up. Change over time for RSES was significant (t(28) = 3.34, p = .012) and the change rate per six months was 0.07 (SE = 0.02). The effect size for change until follow-up was large (d = 0.96). Looking at the clinical cutoff, defined as ranging from 2.6 to 3.4, only three patients were within the range of normal self-esteem at follow-up. Eight patients scored lower than the lower cutoff of 2.6, and two patients scored higher than the upper cutoff of 3.4.

**Work functioning**  
WSAS at start of treatment had a predicted mean of 18.71 (SE = 1.74), and at follow-up the predicted mean of WSAS had dropped to 3.79 (SE = 0.73). For WSAS, the change over 5.5 years was also highly significant (t(28) = -4.13, p = .006) and the change rate per six months was -1.36 (SE = 0.33). The effect size for change until follow-up was large (d = 1.87). In WSAS, the cutoff score between clinical and non-clinical populations lies at 10, and nine out of 13 patients were equal to or below that cutoff score. The remaining four patients were all within the range of 10–20, suggesting functional impairment but less severe clinical symptomology.

**TABLE 4:** Longitudinal outcomes baseline to follow-up.

<table>
<thead>
<tr>
<th>Linear mixed model estimates</th>
<th>Baseline (intercept)/(SE)</th>
<th>Change-rate every 6 months (slope)/(SE)</th>
<th>5.5-year effect size</th>
<th>Cohen's d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom distress (GSI)</td>
<td>1.25 (0.14)</td>
<td>-0.06 (0.02)</td>
<td>1.18</td>
<td></td>
</tr>
<tr>
<td>Interpersonal functioning (CIP)</td>
<td>1.28 (0.10)</td>
<td>-0.03 (0.02)</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>Self-esteem (RSES)</td>
<td>2.34 (0.15)</td>
<td>0.07 (0.02)</td>
<td>0.96</td>
<td></td>
</tr>
<tr>
<td>General functioning (GAF)</td>
<td>46.89 (2.15)</td>
<td>1.90 (0.41)</td>
<td>2.06</td>
<td></td>
</tr>
<tr>
<td>Work/social functioning (WSAS)</td>
<td>18.71 (1.74)</td>
<td>-1.36 (0.33)</td>
<td>1.67</td>
<td></td>
</tr>
</tbody>
</table>
FIGURES 2-6: These figures demonstrate predicted longitudinal trajectories of change based on linear mixed model estimates of secondary outcome variables. The solid line demonstrates the predicted values; shadowed area represents the 95% upper and lower confidence intervals. For clinical interpretation the clinical cut-off line has also been added to the charts at the y-axis.

Treatment retention
Four out of 18 patients (22%) were defined as dropouts (≤ six months in therapy). Five patients did not attend to the follow-up assessment for various reasons, which included saying no, being unavailable, discontentment with therapists, avoiding the appointments, serious injured to one patient after a drug-related accident.

Discussion
The aim of the present study was to investigate whether patients with BPD/SUD could benefit from participating in a specialized treatment, MBT, developed for patients with BPD. Our research questions were: 1) did participants improve on substance use
disorder and 2) did they enter a positive trajectory regarding their BPD? Furthermore, we wanted to investigate participants' improvements on secondary outcome measures: interpersonal functioning, global functioning, social functioning, and symptom severity. The main findings of our study were that patients with BPD/SUD showed significant improvement on both primary and secondary outcome measures. Effect sizes ranged from moderate to very large, with most being large.

**Substance use decline**

This MBT pilot was tailored to deal with the comorbidity of BPD/SUD since the trial happened within a specialized clinic for substance use disorders and all therapists were trained in the treatment of substance use disorder and personality disorder. Thus, a dual focus on both core issues of PD together with a continuous focus on substance use and how to reduce it were imminent during the whole treatment trajectory. Therapists probably also tolerated better (dealt with their countertransference), because of their experience and training, the hardcore realities of patients living in the peripheral life situations of drug and alcohol addiction.

The use of an MBT-oriented social counselor and the focus both psycho-pedagogically and therapeutically on substance use and its relation to mentalizing are somewhat different from how MBT is delivered in other settings. For example, the specific focus on exploring mentalizing failure prior to substance intake is an intervention that needs to be utilized when working with BPD/SUD patients. Our pilot also offered 36 months of treatment as opposed to the original authors who suggest 18 to 24 months (Bateman & Fonagy, 2016). The present study is performed as a pilot, and we had no randomization or control group. Conclusions must be taken with great care. Still, we found our results regarding SUD intriguing.

To our surprise, many of the patients achieved full remission of their SUD. Several of them had long histories with outpatient and inpatient treatment in our own institution and thus were in danger of being viewed upon as chronic patients. We believe that the model of primacy of PD in the etiology of PD/SUD is of interest (Vélez-Moreno et al., 2016; Verheul & van den Brink, 2005). In this pilot, the focus was on increasing patients’ ability to mentalize (an issue related to their PD symptomatology), especially during moments of emotional activation and attachment-related arousal. In MBT, this focus is systematic and continues throughout the whole clinical trajectory.

It seems that by targeting BPD-related problems, there is an effect on SUD for these patients. Other inpatient and outpatient treatments had not achieved these results before. In some studies on Nordic
SUD patients (with high prevalence of PD), the remission of SUD at five- and six-year follow-up after treatment is not that encouraging, with relapse rates at 70% (Landheim et al., 2006) and 54% (Fridell & Hesse, 2006). We performed a two-year follow-up and thus cannot directly compare our findings to the studies above. In another longitudinal study, disappearance of BPD coincided with the disappearance of SUD (Paris & Zweig-Frank, 2001). This tendency converges with our findings where SUD and BPD both demonstrated substantial decline from baseline to follow-up. It also supports the notion that by focusing on BPD-related difficulties through increasing the ability of mentalizing (Philips et al., 2012), there is a possible effect on SUD as well (Outcalt et al., 2016). But there are some who have advocated that SUD must be seen as a chronic disorder and that treatment needs to shift focus from curing the disorder to symptom relief (McLellan, 2002). Our findings contradict this perspective and give a tentatively more positive view on SUD (and comorbid PD). There is perhaps a possibility of treating both disorders, given targeted treatments.

**Reduction of borderline symptomology**

MBT is a tailored treatment for BPD (Bateman & Fonagy, 2016), and assessing whether patients still have BPD after completion of treatment is thus important. In our study, both the number of personality disorder criteria declined, and the diagnosis of BPD disappeared at follow-up. This is quite encouraging with respect to the efficiency of MBT with this dual diagnosis patient group, and it supports the notion that MBT is increasingly efficient in line with the severity of the patient group pathology (Bateman & Fonagy, 2013). Two patients still fulfilled the criteria for BPD at follow-up. These patients deserve detailed case studies. The decline in both borderline personality disorder and substance use disorder during the same clinical trajectory supports the notion that PD and SUD are connected and causally connected to each other in some way. Three models have been proposed on the interconnectedness of PD/SUD, and most support lies with the model where PD is primary to SUD (Verheul & van den Brink, 2005).

**Improvement in social functioning, self-esteem, and symptomatic distress**

Overall the results on our secondary outcome measures demonstrate improvement. For all our outcome measures except for interpersonal functioning, the predicted trajectories lie within the non-clinical domain at follow-up. On self-esteem, symptom distress, general functioning, and work and social functioning, patients reach non-clinical levels. These results are quite encouraging. Interpersonal functioning does significantly change from baseline to follow-up but does not at any point reach non-clinical levels. Treating
dual diagnosis patients with comorbid personality disorder is challenging. We are just getting started in gaining enough knowledge on what these patients need for positive change trajectories. Many of our patients in this pilot reached symptomatic improvement and remission of SUD and PD. Further follow-up studies need to be performed to investigate if these changes endure in the longitudinal trajectory of MBT patients.

**Do BPD/SUD patients have unique trajectories regarding GSI and CIP?**

Do they get worse before they get better? Our sample of dual diagnosis patients reported lower symptom distress on the GSI at baseline than patients with BPD alone; see for instance Bateman & Fonagy (2009), Kvarstein et al. (2015), and Laurensen et al. (2013). GSI in these studies were respectively 2.0, 2.1, and 2.2 versus our sample who reported predicted baseline levels of GSI to be 1.3. The one MBT study that had a sample of BPD patients where 79% had comorbid SUD also demonstrated their baseline symptom distress scores to be somewhat lower than the studies above, at 1.7 (Bales et al., 2012).

The patients in our sample also had lower CIP sum scores on baseline (1.3) than other studies with borderline personality disorder (2.0, 1.7) (Bateman & Fonagy, 2009; Kvarstein et al., 2015). We think this tendency demonstrates how SUD intervenes with the subjective experience of interpersonal problems and symptom distress. Substance use has been suggested to function as a regulator of emotional activation, particularly during moments of an activated attachment system (Philips et al., 2012). This hypothesis converges with theories in the field where substance use has been suggested to potently interfere with attachment needs (Cihan, Winstead, Laulis, & Feit, 2014; Insel, 2003). This gives indices that the psychotherapeutic trajectory for BPD/SUD patients could possibly involve a worsening of the subjective experience of symptom severity and interpersonal functioning when and if their substance use declines. These nonlinear change trajectories were not possible to model in this study due to a low number of n.

The reasons for these discrepancies between BPD/SUD patients and BPD alone are unknown and require further empirical investigation. We speculate the following: 1) substance use has an effect on the subjective experience of symptom distress and interpersonal functioning and 2) BPD/SUD patients have unique trajectories during psychotherapy on symptom distress and interpersonal functioning.

Further studies are needed to investigate these hypotheses on the uniqueness of BPD/SUD trajectories of change in psychotherapy.
Treatment retention
Dropout in the treatment of BPD/SUD group of patients is a common problem (Ball et al., 2006; Broerson et al., 2013). Therapeutic alliance can be a challenge for SUD patients with Cluster B traits (Olesek et al., 2016). Defining dropout as equal to or less than six months of treatment, we had in our study four out of 18 patients dropping out (22%). Our dropout rate is lower than numbers reported from other studies with dual diagnosis patients. In dual diagnosis DBT studies, the dropout rates have ranged from 36% to 55% (Axelrod, Perepletchikova, Holtzman, & Sinha, 2011; Linehan et al., 2002; Linehan et al., 1999). In MBT studies with BPD alone, the dropout rate has varied from 5% to 43% (Jørgensen et al., 2013; Kvarstein et al., 2015).

The problem is that the respective studies above do not define dropout equally. Our dropout definition is equivalent to Kvarstein and colleagues (2015) (5%), and it seems that compared with them, our dropout rate is too high. Nevertheless, a dropout rate of 22% is acceptable with a patient group known for problems with alliance and treatment retention. We suggest, however, that further empirical investigations would shed light on the reasons for dropout in this patient group, so that we could better tailor our treatment programs.

Strength and limitations
There are several problems with this study, which implies that the conclusions should be taken with great care. First, the study did not involve any control group or randomization. Thus, we cannot conclude that the changes these patients underwent were caused by the actual treatment. In the natural trajectory of BPD patients, symptomatic and personality distress does improve with the passage of time (Gunderson et al., 2011; Zanarini, Frankenburg, Hennen, & Silk, 2003). However, these patients' social functioning is less amenable to improvement and the prognosis is worse when combined with SUD (Fridell & Hesse, 2006; Walter et al., 2009).

Second, the number of patients was very small, as is often a problem in treatment studies of BPD/SUD patients. The statistical analyses were limited by the small n, and the only analyses we could perform were to substantiate that changes had occurred. Nonlinear change trajectories could not be investigated, and comparisons between different subgroups in the sample were not possible (e.g., dropouts vs. treated patients).

Third, we did not have any endpoint data on five patients. A full data set might have influenced the results in a negative manner. The response of some participants to our request might indicate that they still have significant personality problems. The duration of their treatments was also lower than our follow-up completers. We would
also like to mention that supervisors and trainers from the Norwegian Institute of Mentalizing were involved, which could generate a positive bias. However, the most obvious contribution of these trainers and supervisors was to secure adherence to and the quality of the treatment that was delivered.

Finally, the diagnostics of the primary outcome measures and GAF at follow-up was performed by the first and fourth author together. The lack of blinding and investment in the study could bias the results.

A considerable strength of the study was its ecological validity (i.e., that it was conducted in a clinical naturalistic setting). It is also noteworthy that all patients had multiple experiences with former treatments, both inpatient and outpatient treatments, and most of them from the same clinic where this pilot was performed. Earlier treatment had not had any lasting effect on their personality disorder or SUD.

Conclusion

Patients suffering from both severe personality disorder of the borderline type and substance abuse are known to be difficult to treat and have a very poor prognosis. Our study indicates that MBT might be a promising treatment modality for this comorbid condition. We found that for the majority of the patients, their drug and alcohol consumption and personality problems improved considerably. However, the results for the cohort as a whole are somewhat uncertain since 28% of the patients did not respond to follow-up. Furthermore, because this was a feasibility study, our findings indicate that MBT is implementable in a drug clinic, that clinicians and patients find the treatment protocol acceptable, and that data can be routinely collected. These favorable results indeed call for a larger randomized study.

References


Vélez-Moreno, A., Rojas, A. J., Rivera, F., Fernández-Calderón, F.,


Citation


Abstract

Mentalization-based treatment for female patients with comorbid personality disorder and substance use
disorder: A pilot study

Objectives: In this study, we investigated the feasibility of mentalization-based treatment (MBT) for patients with comorbid substance use disorder (SUD) and borderline personality disorder (BPD). No published study has ever specifically looked at MBT for these patients. Such individuals are known to have a very poor prognosis and harbor much pain and misery. Moreover, few randomized controlled trials exist on psychotherapy efficiency for patients with comorbid substance use disorder and borderline personality disorder. There is an urgent need for more knowledge on treatment for this patient group.

Design: A pilot project within a naturalistic clinical setting with longitudinal data collection during treatment and at follow-up. Eighteen female patients attended a pilot project and participated in up to 36 months of treatment, according to the manuals. Patients were measured on primary (pre/post) and secondary (longitudinal) outcome measures before treatment, every six months during treatment, at the end of treatment, and at follow-up approximately two years after treatment.

Methods: Statistical analyses of repeated outcome measures (GSI, CIP, GAF, WSAS, and RSES) and of pre/post measures (Axis I and II diagnosis) were performed with linear mixed models, and Cohens d was calculated.

Results: Significant improvements on primary and secondary outcome measures were demonstrated, with effect sizes ranging from moderate to large. With respect to primary outcome, these SUD/PD patients were almost fully recovered from their SUD at follow-up (a predicted score of 0.2 Axis I SUD diagnosis at follow-up in comparison with a score of 1.8 at baseline).

Conclusion: MBT as performed in this pilot project indicates promising results for patients with (mostly borderline) PDs and comorbid SUDs. Performing RCT studies is warranted.

Keywords: borderline personality disorder, linear mixed models, mentalization, pilot study, psychotherapy, substance use disorder.

Author affiliations: Katharina T. E. Morken – MBT team, The Bergen Clinic Foundation, Bergen, Norway, & Department of clinical psychology, University of Bergen, Bergen, Norway; Per-Einar Binder & Helge Molde – Department of clinical psychology, University of Bergen, Bergen, Norway; Nina Arefjord – Competence Centre on Drug and Alcohol, The Bergen Clinic Foundation, Bergen, Norway; Sigmund Karterud – The Norwegian Institute of Mentalizing, Oslo, Norway.

Contact information: Katharina T. E. Morken, Vestre Torgt. 11, N-5013 Bergen, Norway. Email: kthm@bergensklinikkene.no.
Received: July 27, 2017. Accepted: November 26, 2017.
Published: December 8, 2017.

Language: English.

Competing interests: The authors report no conflict of interest. The authors alone are responsible for the contents and writing of this paper.

This is a peer-reviewed paper.